Navigation Links
Findings on pollution damage to human airways could yield new therapies

DURHAM, N.C. Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.

The scientists also discovered that the severity of the injury depends on the genetic make-up of the affected individual.

"We gained insight into why some people can remain relatively healthy in polluted areas and why others don't," said lead author Wolfgang Liedtke, M.D., Ph.D., assistant professor in the Duke Department of Medicine and an attending physician in the Duke Clinics for Pain and Palliative Care.

The work was published on-line in the journal Environmental Health Perspectives on Jan. 18.

Diesel exhaust particles, a major part of urban smog, consist of a carbon core coated with organic chemicals and metals. The Duke team showed that the particle core delivers these organic chemicals onto brush-like surfaces called cilia, which clear mucus from the airway lining.

Contact with these chemicals then triggers a "signaling cascade," as the cells respond.

In some patients, who have a single "letter" difference in their DNA, a circuit called the TRPV4 ion channel signals more strongly in response to the pollutants. Previous research showed that this gene variant makes humans more liable to develop chronic-obstructive disease (COPD), and the current study provides an explanation for this observation.

About 75 percent of people have the version of the gene MMP-1 that leads to greater production of the molecule MMP-1 mediator, which destroys lung tissue. This genetic make-up allows for a turbo-charged production of MMP-1, which damages airways and lungs at multiple levels, Liedtke said.

A more fortunate 25 percent of people escape this high level of production of MMP-1, which may be reflected in the fact that certain individuals can better manage the effects of air pollution without grave airway damage.

The injurious molecule MMP-1 is known to enhance the development of certain devastating lung diseases, such as chronic-obstructive pulmonary disease (COPD), a top-ten ailment in world-wide morbidity and mortality, according to the World Health Organization. The devastating, tissue-destructive actions of MMP-1 can also lead to lung emphysema, which is chronic reduction of the lung surface dedicated to gaseous exchange, and to the spread of lung cancer cells, through migration of these cells from lung tissue that has become cancerous.

The new study also provides a direction for developing therapeutics for those who are genetically more susceptible to air pollution and airway damage, Liedtke said. "If we can find a way to stop the hyperactivation of MMP-1 in response to diesel-engine exhaust particles and reduce it to levels that the airways can manage, then we will be helping a large number of people worldwide," he said. "It is attractive to envision inhaled TRPV4 inhibitor drugs, rather than swallowing a pill or taking an injection. I envision this as rather similar to inhaled drugs for allergic airway disease that are currently available."


Contact: Mary Jane Gore
Duke University Medical Center

Related biology news :

1. September 2007 Sumatran earthquakes research findings
2. Findings uncover new details about mysterious virus
3. Nearly a century later, new findings support Warburg theory of cancer
4. New research findings may enable earlier diagnosis of uterine cancer
5. Therapeutic cloning gets a boost with new research findings
6. International climate change researchers meet, review latest findings
7. Findings show insulin -- not genes -- linked to obesity
8. FANTOM findings boost for biologists
9. New findings in taste and smell
10. SRI International announces findings from new upper atmospheric radar system for scientific research
11. USC researchers present diabetes findings at American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
Breaking Biology Technology: